Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07226193 · ClinicalTrials.gov registry record · NA

Detecting Peripheral Artery Disease With the Pulse

A NA study of Peripheral Artery Disease (PAD), sponsored by University of Nebraska.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT07226193 is a NA study of Peripheral Artery Disease (PAD) that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 40 participants, below the 281-participant average among 5 other Peripheral Artery Disease (PAD) trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07226193, a NA study of Peripheral Artery Disease (PAD), is actively recruiting participants, sponsored by University of Nebraska.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

1\) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD), and to investigate the impacts of local skin heating and foot elevation. The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to both middle fingers and both big toes. Signals will be collected for 15-min with finger and toe sensor temperatures at 30 C. Toe sensor temperature will then be elevated to 45 C for 15-min. Finally, toe sensor temperature will remain at 45 C, and the feet will be elevated 8-in with a soft cushion for 15-min. Blood pressure in the foot will be assessed before and after foot elevation with Doppler ultrasound. Thermal images of the finger

Interventions

  • DEVICE Segmental pulse arrival time assessment

Study Locations (1)

Nebraska

  • University of Nebraska at Omaha Health Science Collaborative - Omaha

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-02-05
Est. Completion 2027-01-01
Phase NA

Sponsor

University of Nebraska

407 total trials

What the Registry Record Tells You About NCT07226193

The ClinicalTrials.gov registry entry for NCT07226193 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 5 other Peripheral Artery Disease (PAD) trials with a reported enrollment target (86% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Artery Disease (PAD) appearing as the primary indexed condition, and to 1 intervention - of which Segmental pulse arrival time assessment is the first listed.

NCT07226193 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT07226193 about?

NCT07226193 is a clinical study titled "Detecting Peripheral Artery Disease With the Pulse". 1\) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD), and to investigate the impacts of local skin heating and foot elevation. The secondary purpose will be to investigate the impacts of ag...

What is the current status of trial NCT07226193?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-02-05. Estimated completion is 2027-01-01.

What conditions does trial NCT07226193 study?

This clinical trial studies the following conditions: Peripheral Artery Disease (PAD).

What interventions are being tested in trial NCT07226193?

The interventions under investigation include: Segmental pulse arrival time assessment (DEVICE).

Who is sponsoring clinical trial NCT07226193?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07226193 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease (PAD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.